Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
8 páginas
| Autores Principales: | , , , , , , , , , |
|---|---|
| Formato: | Artículo (Article) |
| Lenguaje: | Inglés (English) |
| Publicado: |
Clinical Rheumatology
9/4/
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/10818/43203 |
| id |
ir-10818-43203 |
|---|---|
| recordtype |
dspace |
| spelling |
ir-10818-432032022-05-10T10:20:33Z Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis Romero Sánchez, Consuelo Robinson, William H. Tomooka, Beren H. Londoño Patiño, John Darío Valle Oñate, Rafael Huang, Feng Deng, Xiaohu Zhang, Liyun Yang, Chunhua Tak Yan Yu, David Ankylosing spondylitis Biomarkers Infliximab 8 páginas Although most ankylosing spondylitis patients show an apparent clinical response to infliximab therapy, there is considerable individual variation. Because current clinical assessment relies heavily on subjective patient self-evaluation, biomarkers of high sensitivity and specificity are much needed. Here, we assessed potential biomarkers in 47 ankylosing spondylitis patients who received three standard pulses of infliximab. Before each infusion and at week 10, the following were measured: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count, serum levels of metalloproteinase-3 (MMP-3), and 22 different cytokines. We discovered that, 2 weeks after the first infusion, the combination of ESR, CRP, and platelet count distinguished responders from non-responders with 81.3% sensitivity and 72.7% specificity. The distinguishing power was much less when each acute phase reactant was used alone. Among the 22 cytokines, serum IL-1alpha was able to distinguish responders from non-responders at week 6, with sensitivity of 84.9% and specificity of 53.8%. Serum IL-1alpha was probably generated from the joint compartments, as synovial fluid levels were much higher than corresponding serum levels. Although infliximab infusions led to rapid and significant suppression of serum MMP-3 levels, serum MMP-3 levels did not distinguish responders from non-responders. Besides identifying potential biomarkers, our results also demonstrate the usefulness of using sensitivity and specificity to assess usefulness of potential biomarkers. 9/4/2020 16:32 2020-09-04T21:32:19Z 2008-06-20 article publishedVersion Romero-Sánchez, C., Robinson, W.H., Tomooka, B.H. et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 27, 1429–1435 (2008). https://doi.org/10.1007/s10067-008-0941-x https://pubmed.ncbi.nlm.nih.gov/18566849/ https://link.springer.com/article/10.1007%2Fs10067-008-0941-x#citeas http://hdl.handle.net/10818/43203 10.1007/s10067-008-0941-x eng Clinical Rheumatology volume 27, pages1429–1435(2008) Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ openAccess application/pdf Clinical Rheumatology Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana https://intellectum.unisabana.edu.co |
| institution |
Universidad de La Sabana |
| collection |
DSpace |
| language |
Inglés (English) |
| topic |
Ankylosing spondylitis Biomarkers Infliximab |
| spellingShingle |
Ankylosing spondylitis Biomarkers Infliximab Romero Sánchez, Consuelo Robinson, William H. Tomooka, Beren H. Londoño Patiño, John Darío Valle Oñate, Rafael Huang, Feng Deng, Xiaohu Zhang, Liyun Yang, Chunhua Tak Yan Yu, David Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis |
| description |
8 páginas |
| format |
Artículo (Article) |
| author |
Romero Sánchez, Consuelo Robinson, William H. Tomooka, Beren H. Londoño Patiño, John Darío Valle Oñate, Rafael Huang, Feng Deng, Xiaohu Zhang, Liyun Yang, Chunhua Tak Yan Yu, David |
| author_facet |
Romero Sánchez, Consuelo Robinson, William H. Tomooka, Beren H. Londoño Patiño, John Darío Valle Oñate, Rafael Huang, Feng Deng, Xiaohu Zhang, Liyun Yang, Chunhua Tak Yan Yu, David |
| author_sort |
Romero Sánchez, Consuelo |
| title |
Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis |
| title_short |
Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis |
| title_full |
Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis |
| title_fullStr |
Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis |
| title_full_unstemmed |
Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis |
| title_sort |
identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis |
| publisher |
Clinical Rheumatology |
| publishDate |
9/4/ |
| url |
http://hdl.handle.net/10818/43203 |
| _version_ |
1741873615687647232 |
| score |
12,131701 |